|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
00455 TIANDA PHARMA
Nominal 
0.000 (0.000%) | 2023/12 - Final HKD(K$) | %Chg (Compare to Final) | 2022/12 HKD(K$) | 2022/03 HKD(K$) | 2021/03 HKD(K$) | 2020/03 HKD(K$) | |
| Turnover | 532,089 | 29.771% | 410,021 | 509,955 | 474,332 | 491,475 |
| Cost of Sales | (276,557) | 24.924% | (221,380) | (268,732) | (215,345) | (130,461) |
| Gross Profit | 255,532 | 35.459% | 188,641 | 241,223 | 258,988 | 361,014 |
| 2023/12 - Final HKD(K$) | %Chg (Compare to Final) | 2022/12 HKD(K$) | 2022/03 HKD(K$) | 2021/03 HKD(K$) | 2020/03 HKD(K$) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | 0 | -- | 0 | 0 | 0 | 0 | |
| Profit / (Loss) before Taxation | (25,694) | -46.348% | (47,890) | (28,018) | (27,442) | 15,928 | |
| Taxation | 689 | -81.108% | 3,647 | 6,343 | 1,524 | (7,128) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 850 | -73.974% | 3,266 | 1,904 | (1,224) | (5,657) | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | (24,155) | -41.052% | (40,977) | (19,771) | (27,142) | 3,143 | |
| 2023/12 - Final HKD(K$) | %Chg (Compare to Final) | 2022/12 HKD(K$) | 2022/03 HKD(K$) | 2021/03 HKD(K$) | 2020/03 HKD(K$) | |
| Net Finance Costs / (Income) | 1,914 | 7.227% | 1,785 | (1,578) | (2,665) | (4,919) |
| Depreciation & Amortisation | 36,407 | -3.396% | 37,687 | 22,149 | 20,618 | 19,520 |
| Directors' Emoluments | 421 | 33.651% | 315 | 449 | 492 | 492 |
| 2023/12 - Final | %Chg (Compare to Final) | 2022/12 | 2022/03 | 2021/03 | 2020/03 | |
| Auditor's Opinion Status | Disclaimer | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2023/12 - Final | %Chg (Compare to Final) | 2022/12 | 2022/03 | 2021/03 | 2020/03 | |
| EPS (cts) | -1.120 | -41.361% | -1.910 | -0.920 | -1.260 | 0.150 |
| DPS (cts) | 0.260 | -- | 0.260 | 0.820 | 0.260 | 0.130 |
| Dividend Payout Ratio (%) | -- | -- | -- | -- | -- | 86.667% |
| Cash flow per share ($) | (0.023) | -- | 0.036 | (0.004) | (0.018) | (0.009) |
| NBV per share ($) | 0.275 | -- | 0.292 | 0.352 | 0.352 | 0.336 |
| Remarks: | Real time quote last updated: 07/11/2024 07:38 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders ($) | HKD -27,236,000 |
| %Change | 559.947% |
| EPS / (LPS) | HKD -0.013 |
| NBV Per Share ($) | HKD 0.253 |